Clinical Research Directory
Browse clinical research sites, groups, and studies.
Zr-89 Crefmirlimab Berdoxam and Immuno-Positron Emission Tomography for the Imaging of Patients With Resectable Brain Tumors
Sponsor: Jonsson Comprehensive Cancer Center
Summary
This phase I trial studies how well zirconium (Zr)-89 crefmirlimab berdoxam and immuno-positron emission tomography (PET) identifies areas of immune cell activity in patients with brain tumors that can be removed by surgery (resectable). One important predictor of the immune response is the presence and change in CD8 positive (+) tumor infiltrating lymphocytes (TIL) cells. Identifying the presence and changes in CD8+ cells can be challenging, particularly for participants with central nervous system (CNS) tumors, and usually requires invasive procedures such as repeat tissue biopsies, which may not accurately represent the immune status of the entire tumor. Zr-89 crefmirlimab berdoxam is known as a radioimmunoconjugate which consists of a radiolabeled anti-CD8+ minibody whose uptake can be imaged with PET. Upon administration, Zr 89 crefmirlimab berdoxam specifically targets and binds to the CD8+ cells. This enables PET imaging and may detect CD8+ T-cell distribution and activity and may help determine the patient's response to cancer immunotherapeutic agents more accurately. Giving Zr-89 crefmirlimab berdoxam along with undergoing immuno-PET imaging may work better at identifying immune cell activity in patients with resectable brain tumors.
Official title: Biologic Validation of Zr-89 Crefmirlimab Berdoxam CD8+ Minibody ImmunoPET in Human Brain Tumors
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2024-12-05
Completion Date
2028-01-31
Last Updated
2026-02-05
Healthy Volunteers
No
Interventions
Advanced Magnetic Resonance Imaging
Undergo advanced MRI
Brain Surgery
Undergo brain surgery
Electronic Health Record Review
Ancillary studies
Immuno-Positron Emission Tomography Scan
Undergo immuno-PET
Magnetic Resonance Imaging
Undergo MRI
Stereotactic Biopsy
Undergo stereotactic image-guided biopsy
Zirconium Zr 89 Crefmirlimab Berdoxam
Undergo Zirconium Zr 89 Crefmirlimab Berdoxam PET
Locations (1)
UCLA / Jonsson Comprehensive Cancer Center
Los Angeles, California, United States